Shares of NeoGenomics Inc. (NEO) touched a 52-week high of $19.11 earlier this week, driven by the company's consistent revenue growth, enhanced operating efficiency, and stronger financial performance in the oncology testing services sector.
The company provides a wide range of oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com